Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

We performed two phase I trials of the histone deacetylase inhibitor vorinostat combined with either the vascular endothelial growth factor inhibitor pazopanib (NCT01339871) or the proteasome inhibitor ixazomib (NCT02042989) in patients with metastatic TP53 mutant solid tumors. Both trials followed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Wang, Yudong, Janku, Filip, Piha-Paul, Sarina, Hess, Kenneth, Broaddus, Russell, Liu, Lidong, Shi, Naiyi, Overman, Michael, Kopetz, Scott, Subbiah, Vivek, Naing, Aung, Hong, David, Tsimberidou, Apostolia M., Karp, Daniel, Yao, James, Fu, Siqing
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7033174/
https://ncbi.nlm.nih.gov/pubmed/32080210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-58366-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados